title: Intrathecal 5-methoxy-N,N-dimethyltryptamine in mice modulates 5-HT1 and 5-HT3 receptors.
abstract: The antinociceptive effects of intrathecally administered 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a potent 5-HT receptor agonist, were studied in three behavioral tests in mice: the tail-flick test and the intrathecal substance P and N-methyl-D-aspartic acid (NMDA) assays. Intrathecal administration of 5-MeO-DMT (4.6-92 nmol/mouse) produced a significant prolongation of the tail-flick latency. This action was blocked by 5-HT3 and gamma-aminobutyric acidA (GABAA) receptor antagonists but not by 5-HT2, 5-HT1A, 5-HT1B or 5-HT1S receptor antagonists. Binding studies indicated that 5-MeO-DMT had very low affinity for 5-HT3 receptors. 5-MeO-DMT inhibited biting behavior while increasing scratching behavior induced by intrathecally administered substance P. The inhibition of biting behavior was antagonized by intrathecal co-administration of 5-HT1B and GABAA receptor antagonists while 5-HT1A, 5-HT1S, 5-HT2 and 5-HT3 receptor antagonists had no effect. 5-MeO-DMT-enhanced scratching behavior was inhibited by all the antagonists used except ketanserin and bicuculline, suggesting the involvement of 5-HT1A, 5-HT1B, 5-HT1S, 5-HT3 and GABAA receptors. NMDA-induced biting behavior was inhibited by 5-MeO-DMT pretreatment; this action was antagonized by 5-HT1B, 5-HT3 and GABAA receptor antagonists. The involvement of these receptors in 5-MeO-DMT action suggests that it may promote release of 5-HT (5-hydroxytryptamine, serotonin).
authors.affiliation: Department of Pharmacology, Medical School, University of Minnesota, MN 55455.
authors.forename: A A
authors.initials: AA
authors.lastname: Alhaider
authors.forename: M
authors.initials: M
authors.lastname: Hamon
authors.forename: G L
authors.initials: GL
authors.lastname: Wilcox
mesh_terms: D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001667:Binding, Competitive / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D066298:In Vitro Techniques; D007278:Injections, Spinal; D008297:Male; D008732:Methoxydimethyltryptamines / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D051379:Mice; D016202:N-Methylaspartate / Q000494:pharmacology; D009619:Nociceptors / Q000187:drug effects / Q000378:metabolism; D009638:Norepinephrine / Q000502:physiology; D016627:Oxidopamine / Q000494:pharmacology; D010147:Pain Measurement / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D011985:Receptors, Serotonin / Q000187:drug effects*; D013373:Substance P / Q000494:pharmacology
chemical_list: D000700:Analgesics; D008732:Methoxydimethyltryptamines; D011985:Receptors, Serotonin; D013373:Substance P; D016202:N-Methylaspartate; D016627:Oxidopamine; D009638:Norepinephrine